Publications by authors named "Mark Kockx"


Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods.

Arch Pathol Lab Med 2018 08 2;142(8):982-991. Epub 2018 Apr 2.

From the Departments of Immunohistochemistry (Drs Schats, Van Vré, Boeckx, and Schrijvers and Ms De Bie) and Molecular Pathology (Dr Kockx), HistoGeneX, Antwerp, Belgium; the Department of Medical Biochemistry, University of Antwerp, Antwerp, Belgium (Drs Schats and De Meester); and the Department of Medical Oncology, Universitair Ziekenhuis Brussel, Belgium (Dr Neyns).

View Article and Find Full Text PDF
August 2018

Histopathological growth patterns as a candidate biomarker for immunomodulatory therapy.

Semin Cancer Biol 2018 10 31;52(Pt 2):86-93. Epub 2018 Jan 31.

Translational Cancer Research Unit (CORE), Gasthuiszusters Antwerpen Hospitals, University of Antwerp, Wilrijk, Antwerp, Belgium; HistoGeneX NV, Wilrijk, Antwerp, Belgium. Electronic address:

View Article and Find Full Text PDF
October 2018

Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.

J Natl Cancer Inst 2017 11;109(11)

Genentech Inc., South San Francisco, CA; F Hoffmann-La Roche Ltd, Basel, Switzerland; NRG Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY; University of Oklahoma, Oklahoma City, OK; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Pennsylvania, Philadelphia, PA; Center for Cancer Research, Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; HistoGeneX NV, Antwerp, Belgium; Division of Physiopharmacology, University of Antwerp, Antwerp, Belgium.

View Article and Find Full Text PDF
November 2017